Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
Ju-Fang Chang(Washington University in St. Louis), Nathan Singh(Unknown), Sangya Agarwal(Amgen (United States)), Joseph A. Fraietta(University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), Nils Wellhausen(University of Pennsylvania), Caitlin R. Hopkins(University of Pennsylvania), Jack H. Landmann(Washington University in St. Louis), Mehmet Emrah Selli(Washington University in St. Louis), Gerald P. Linette(University of Pennsylvania), Julie K. Jadlowsky(University of Pennsylvania), January Salas-McKee(University of Pennsylvania), Adham S. Bear(California University of Pennsylvania), Nils W. Engel(University of Pennsylvania), Carl H. June(University of Pennsylvania)
Cited by 2
Related Papers
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
|American Journal of Hematology|2019|608
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
|JCI Insight|2018|573
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554